Cargando…
Alzheimer’s cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans: CSF AD biomarkers measured by Lumipulse in Koreans
BACKGROUND: Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarker cutoffs from immunoassays with low interlaboratory variability in diverse ethnic groups are necessary for their use in clinics and clinical trials. With lack of cutoffs from fully automated immunoassay platforms in diverse race...
Autores principales: | Moon, Sohee, Kim, Sujin, Mankhong, Sakulrat, Choi, Seong Hye, Vandijck, Manu, Kostanjevecki, Vesna, Jeong, Jee Hyang, Yoon, Soo Jin, Park, Kyung Won, Kim, Eun-Joo, Yoon, Bora, Kim, Hee Jin, Jang, Jae-Won, Hong, Jin Yong, Park, Dong-Ho, Shaw, Leslie M., Kang, Ju-Hee |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802266/ https://www.ncbi.nlm.nih.gov/pubmed/33436035 http://dx.doi.org/10.1186/s13195-020-00767-3 |
Ejemplares similares
-
Analytical evaluation of the novel Lumipulse G BRAHMS procalcitonin immunoassay
por: Ruzzenente, Orazio, et al.
Publicado: (2016) -
Clinical utility of cerebrospinal fluid biomarkers measured by LUMIPULSE(®)
system
por: Nojima, Hisashi, et al.
Publicado: (2022) -
Comparing CSF amyloid‐beta biomarker ratios for two automated immunoassays, Elecsys and Lumipulse, with amyloid PET status
por: Willemse, Eline A. J., et al.
Publicado: (2021) -
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2020) -
Concordance of CSF measures of Alzheimer's pathology with amyloid PET status in a preclinical cohort: A comparison of Lumipulse and established immunoassays
por: Keshavan, Ashvini, et al.
Publicado: (2021)